[
  {
    "ts": null,
    "headline": "AMGN Stock Down Despite Strong Data From Obesity Drug Study",
    "summary": "Data from a phase II study shows that AMGN's obesity drug MariTide leads to sustainable weight loss, robust improvements in cardiometabolic parameters and strong HbA1c reduction.",
    "url": "https://finnhub.io/api/news?id=07e70f2622e1005838769252ca20a011c1fb97ec987abd67351d96f53b40545a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732737600,
      "headline": "AMGN Stock Down Despite Strong Data From Obesity Drug Study",
      "id": 131683017,
      "image": "https://media.zenfs.com/en/zacks.com/08c70fc44d9b8340859581d38311e071",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Data from a phase II study shows that AMGN's obesity drug MariTide leads to sustainable weight loss, robust improvements in cardiometabolic parameters and strong HbA1c reduction.",
      "url": "https://finnhub.io/api/news?id=07e70f2622e1005838769252ca20a011c1fb97ec987abd67351d96f53b40545a"
    }
  },
  {
    "ts": null,
    "headline": "Amgen's Phase 2 Results Were Not Bad, Don't Let Mr. Market Fool You",
    "summary": "Amgen's MariTide shows promising weight loss results in Phase II for type 2 diabetes. Find out why AMGN stock remains as a strong buy for long-term investors.",
    "url": "https://finnhub.io/api/news?id=6ada056afb7a7e9c6f36ad52e53f0ddc8676801915d49dd3d504b20a7f67c12f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732712818,
      "headline": "Amgen's Phase 2 Results Were Not Bad, Don't Let Mr. Market Fool You",
      "id": 131670183,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1219304818/image_1219304818.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Amgen's MariTide shows promising weight loss results in Phase II for type 2 diabetes. Find out why AMGN stock remains as a strong buy for long-term investors.",
      "url": "https://finnhub.io/api/news?id=6ada056afb7a7e9c6f36ad52e53f0ddc8676801915d49dd3d504b20a7f67c12f"
    }
  },
  {
    "ts": null,
    "headline": "Amgen's Obesity Candidate MariTide Must Mitigate Tolerability Issues to Compete with Blockbuster Tirzepatide, Truist Says",
    "summary": "Amgen's (AMGN) investigational drug MariTide is a good opportunity for the company to enter the obes",
    "url": "https://finnhub.io/api/news?id=d2e7b8be8dedfac1272cff4d9dbb647b281fc7cce582938358d8dd275849deea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732711489,
      "headline": "Amgen's Obesity Candidate MariTide Must Mitigate Tolerability Issues to Compete with Blockbuster Tirzepatide, Truist Says",
      "id": 131668502,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen's (AMGN) investigational drug MariTide is a good opportunity for the company to enter the obes",
      "url": "https://finnhub.io/api/news?id=d2e7b8be8dedfac1272cff4d9dbb647b281fc7cce582938358d8dd275849deea"
    }
  },
  {
    "ts": null,
    "headline": "Amgen’s MariTide shows up to 20% average weight loss in Phase 2 study",
    "summary": "Amgen (AMGN) announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide – maridebart cafraglutide, formerly AMG 133 -, an investigational antibody peptide conjugate subcutaneously administered monthly or less frequently. In people living with obesity or overweight without Type 2 diabetes, MariTide demonstrated up to ~20% average weight loss at week 52 without a weight loss plateau, indicating the potential for further weight loss beyond 52 weeks. People livin",
    "url": "https://finnhub.io/api/news?id=9c0fe370a2385dcadb5a30b3b5602d21cc11037a2ab547bc5d9dd97714b1617a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732709455,
      "headline": "Amgen’s MariTide shows up to 20% average weight loss in Phase 2 study",
      "id": 131668505,
      "image": "https://media.zenfs.com/en/tipranks_452/8320c2fcdb98599e6484b3e7bdbec8a5",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (AMGN) announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide – maridebart cafraglutide, formerly AMG 133 -, an investigational antibody peptide conjugate subcutaneously administered monthly or less frequently. In people living with obesity or overweight without Type 2 diabetes, MariTide demonstrated up to ~20% average weight loss at week 52 without a weight loss plateau, indicating the potential for further weight loss beyond 52 weeks. People livin",
      "url": "https://finnhub.io/api/news?id=9c0fe370a2385dcadb5a30b3b5602d21cc11037a2ab547bc5d9dd97714b1617a"
    }
  },
  {
    "ts": null,
    "headline": "AMGEN ANNOUNCES ROBUST WEIGHT LOSS WITH MARITIDE IN PEOPLE LIVING WITH OBESITY OR OVERWEIGHT AT 52 WEEKS IN A PHASE 2 STUDY",
    "summary": "THOUSAND OAKS - Amgen today announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide , an investigational antibody peptide conjugate subcutaneously administered...",
    "url": "https://finnhub.io/api/news?id=a26a139ac64aa0eea2f6d7a0ff56ffd742507dd9780ed70ab4813d0d534207ff",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732702575,
      "headline": "AMGEN ANNOUNCES ROBUST WEIGHT LOSS WITH MARITIDE IN PEOPLE LIVING WITH OBESITY OR OVERWEIGHT AT 52 WEEKS IN A PHASE 2 STUDY",
      "id": 131667463,
      "image": "",
      "related": "AMGN",
      "source": "Finnhub",
      "summary": "THOUSAND OAKS - Amgen today announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide , an investigational antibody peptide conjugate subcutaneously administered...",
      "url": "https://finnhub.io/api/news?id=a26a139ac64aa0eea2f6d7a0ff56ffd742507dd9780ed70ab4813d0d534207ff"
    }
  },
  {
    "ts": null,
    "headline": "Why Amgen's Weight Loss Result Is a Win for Eli Lilly",
    "summary": "Shares of Amgen (NASDAQ: AMGN) recently ticked lower despite a very positive-sounding press release regarding its weight management candidate.  According to the giant drugmaker, treatment with an anti-obesity candidate called MariTide helped patients reduce their weight by up to 20% after 52 weeks.  On the surface, 20% weight loss after 52 weeks for a monthly injection is commendable.",
    "url": "https://finnhub.io/api/news?id=6d52334313737c2e2566c814425b57af70df048f4b50e8a8fb6e5f9a57b5205f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732697820,
      "headline": "Why Amgen's Weight Loss Result Is a Win for Eli Lilly",
      "id": 131664647,
      "image": "https://g.foolcdn.com/editorial/images/799133/investor-doing-stuff-getty.jpg",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Shares of Amgen (NASDAQ: AMGN) recently ticked lower despite a very positive-sounding press release regarding its weight management candidate.  According to the giant drugmaker, treatment with an anti-obesity candidate called MariTide helped patients reduce their weight by up to 20% after 52 weeks.  On the surface, 20% weight loss after 52 weeks for a monthly injection is commendable.",
      "url": "https://finnhub.io/api/news?id=6d52334313737c2e2566c814425b57af70df048f4b50e8a8fb6e5f9a57b5205f"
    }
  },
  {
    "ts": null,
    "headline": "What Holidays? Inflation, Black Friday, Bitcoin, and More Market Concerns This Thanksgiving. And 5 Other Things to Know Today.",
    "summary": "What Holidays? Inflation, Black Friday, Bitcoin, and More Market Concerns This Thanksgiving. And 5 Other Things to Know Today.",
    "url": "https://finnhub.io/api/news?id=65fc320c0e0fa9ec65fe2a225ba6a9f92dae1916b0b065278297a418f25976fe",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732691400,
      "headline": "What Holidays? Inflation, Black Friday, Bitcoin, and More Market Concerns This Thanksgiving. And 5 Other Things to Know Today.",
      "id": 131774957,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "What Holidays? Inflation, Black Friday, Bitcoin, and More Market Concerns This Thanksgiving. And 5 Other Things to Know Today.",
      "url": "https://finnhub.io/api/news?id=65fc320c0e0fa9ec65fe2a225ba6a9f92dae1916b0b065278297a418f25976fe"
    }
  },
  {
    "ts": null,
    "headline": "Amgen: Checks All The Wrong Boxes",
    "summary": "Amgen's dividend yield is not attractive enough, and the stock's technical damage indicates further potential declines. See why AMGN is a Sell.",
    "url": "https://finnhub.io/api/news?id=bd081b0cb6b9581c7ca9e2ee7d143fd1c69bc853e86fcefc1230cd27f5e8bd81",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732682385,
      "headline": "Amgen: Checks All The Wrong Boxes",
      "id": 131662391,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1204124144/image_1204124144.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Amgen's dividend yield is not attractive enough, and the stock's technical damage indicates further potential declines. See why AMGN is a Sell.",
      "url": "https://finnhub.io/api/news?id=bd081b0cb6b9581c7ca9e2ee7d143fd1c69bc853e86fcefc1230cd27f5e8bd81"
    }
  },
  {
    "ts": null,
    "headline": "Unexpected Results In Hatch Waxman Litigation: A Review Of Legal Decisions From 2023",
    "summary": "Patent owners generally look to secondary indicia to bolster their nonobvious defenses when prior art and/or knowledge of a person of ordinary skill in the art seem to make the obviousness decision a...",
    "url": "https://finnhub.io/api/news?id=0a97772bf26d8eb9cd62f6c9abc979f008aa091e54d1ea58505397061fdd9081",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732677188,
      "headline": "Unexpected Results In Hatch Waxman Litigation: A Review Of Legal Decisions From 2023",
      "id": 131660870,
      "image": "",
      "related": "AMGN",
      "source": "Finnhub",
      "summary": "Patent owners generally look to secondary indicia to bolster their nonobvious defenses when prior art and/or knowledge of a person of ordinary skill in the art seem to make the obviousness decision a...",
      "url": "https://finnhub.io/api/news?id=0a97772bf26d8eb9cd62f6c9abc979f008aa091e54d1ea58505397061fdd9081"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Breakfast Podcast: Trump's Tariff Threats, Fed Signals",
    "summary": "Investors set aside Trump's new tariff threats and Fed signals moderate pace in cutting rates.",
    "url": "https://finnhub.io/api/news?id=da6dbd2fe4cf3c8c507d5be305b743a9e2d3231c9252c2f4325b20d97ee09e80",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732676465,
      "headline": "Wall Street Breakfast Podcast: Trump's Tariff Threats, Fed Signals",
      "id": 131660793,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1027441788/image_1027441788.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Investors set aside Trump's new tariff threats and Fed signals moderate pace in cutting rates.",
      "url": "https://finnhub.io/api/news?id=da6dbd2fe4cf3c8c507d5be305b743a9e2d3231c9252c2f4325b20d97ee09e80"
    }
  }
]